Abstract 567P
Background
Leptomeningeal metastasis (LM) is one of the most severe complications of non-small cell lung cancer (NSCLC) and is always accompanied by poor prognosis. The optimal treatment for EGFR–mutated NSCLC patients with LM after EGFR-TKI therapy failure remains unclear. Furmonertinib is a novel third-generation EGFR-TKI. A phase I-II dose-expansion study (NCT03127449) suggested that furmonertinib had a favorable antitumor activity with a wide therapeutic range and minimal toxicity. This retrospective study aimed to evaluate the efficacy and safety of furmonertinib 160mg in combination with bevacizumab and intrathecal chemotherapy in EGFR-mutated NSCLC patients with LM after initial TKI failure in the real world.
Methods
We retrospectively studied 19 NSCLC pts with LM treated with furmonertinib in combination with bevacizumab and intrathecal chemotherapy between February 2021 and April 2023 at Nanjing Chest Hospital. All of them received third-generation EGFR TKIs-based therapies previously. Objective response rate (ORR), disease control rate (DCR), progression free survival (PFS), and toxicity were assessed.
Results
The median age was 57 years (range: 31-77), 6 (31.6%) were males and 13 (68.4%) were females. 4 (21.1%) had EOCG 2, 7 (36.8%) had ECOG 3, and 8 (42.1%) had ECOG 4. 16 patients (84.2%) had partial remission (PR) of LM lesions, 3 patients (15.8%) had stable disease (SD). The intracranial ORR (iORR) was 84.2% and intracranial DCR (iDCR) was 100%. 5 patients achieved PR and 14 patients had SD in the whole lesion, ORR was 26.3% and DCR was 100%. Median PFS was 11.9 months (95% CI 2.8–21.0). The overall survival data were not mature (the overall maturity was 26%). Treatment-related adverse events of ≥ grade 3 occurred in only 1 (5.3%) of 19 patients. Safety profile consistent with previous studies of furmonertinib.
Conclusions
Rechallenges of furmonertinib in combination with bevacizumab and intrathecal chemotherapy has shown significant efficacy and tolerable safety profile in EGFR–mutated NSCLC patients with LM after third-generation EGFR-TKIs treatment failure. The further exploration is ongoing.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
414P - Landscape of ERBB2 mutations in advanced cancers (AC) using circulating tumor DNA (ctDNA) next-generation sequencing (NGS) in Asia and Middle East (AME)
Presenter: Byoung Chul Cho
Session: Poster Display
Resources:
Abstract
415P - Initial experience in a real-world Asian cohort with a circulating tumor DNA (ctDNA) mutation-based multi-cancer early detection (MCED) assay
Presenter: Steven Tucker
Session: Poster Display
Resources:
Abstract
416P - Three-dimensional bioprinting model of ovarian cancer for identification of patient-specific therapy response
Presenter: Jiangang Zhang
Session: Poster Display
Resources:
Abstract
417P - Early experience in using plasma-only multi-omic minimal residual disease testing in early-stage colorectal cancer patients from Asia and the Middle East
Presenter: Shaheenah Dawood
Session: Poster Display
Resources:
Abstract
418P - Decoding the intricate cellular makeup of immune-related adverse events using single-cell and spatial analysis
Presenter: Dmitrii Shek
Session: Poster Display
Resources:
Abstract
420P - Combinatory genomic and transcriptomic sequencing of Chinese KRAS mutant non-small cell lung cancer revealed molecular and inflammatory heterogeneity in tumor microenvironment
Presenter: Xuchao Zhang
Session: Poster Display
Resources:
Abstract
421P - Comprehensive genomic profiling (CGP) unravels somatic BRCA (sBRCA) and homologous recombinant repair (HRR) gene alterations across multi-cancer spectrum
Presenter: Ramya Kodandapani
Session: Poster Display
Resources:
Abstract
422P - CD8Teff distinguished tumor immunotyping heterogeneity and enables precision immunotherapy
Presenter: luhui Mao
Session: Poster Display
Resources:
Abstract
423P - Insights into clinically actionable biomarkers in an Indian cancer cohort of 1000 patients using comprehensive genomic profiling (CGP)
Presenter: Mithua Ghosh
Session: Poster Display
Resources:
Abstract
424P - MD Anderson Cancer Center global precision oncology decision support (Glo-PODS) clinical trial genomic support: Pilot program at the Prince of Wales Hospital (Chinese University of Hong Kong - CUHK)
Presenter: Brigette Ma
Session: Poster Display
Resources:
Abstract